Filing Flows

Filing Flows › Companies › LifeMD › Cash flow

LifeMD cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$8.6M in Q2 2026 · −$11.1M over twelve months

Operating cash flow−$6.9M
Capital spending−$1.7M
Free cash flow−$8.6M
Cash conversion cycle-270 days

Analysis

In Q2 2026, LifeMD generated −$6.9M of operating cash flow and spent $1.7M on capital projects, leaving free cash flow of −$8.6M. That is $14.5M less than in Q2 2025 ($5.8M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$9.9M; the largest uses were operating cash flow ($9.9M), other financing ($7.9M), dividends ($3.1M); besides operations, cash came from other investing ($10.9M); the cash balance fell by $11.1M.

Operating cash flow was −$6.9M against net income of −$7.1M. The largest differences: deferred revenue +$44.8M, payables −$3.5M, accrued liabilities +$1.7M.

Its cash conversion cycle was -270 days (receivables 20 + inventory 53 − payables 343): suppliers fund its working capital.

Free cash flow

LifeMD: free cash flow by quarterLifeMD: free cash flow by quarter$6.3MQ3 2024$875KQ4 2024$1.1MQ1 2025$5.8MQ2 2025−$968KQ3 2025−$3.4MQ4 2025−$1.6MQ1 2026−$8.6MQ2 2026
Operating cash flow less capital spending.
LifeMD: operating cash flow against capital spendingLifeMD: operating cash flow against capital spendingOperating cash flowCapital spending$6.7M$448KQ3 2024$1.1M$198KQ4 2024$3.1M$2.0MQ1 2025$8.6M$2.8MQ2 2025−$147K$821KQ3 2025−$3.3M$155KQ4 2025$445K$2.0MQ1 2026−$6.9M$1.7MQ2 2026
Latest (Q2 2026): Operating cash flow −$6.9M, Capital spending $1.7M.

Capital allocation, year by year

LifeMD: where the cash came from (up) and went (down), by fiscal yearLifeMD: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingAcquisitionsBuybacksDividendsFY2021: Operating cash flow −$33.1MFY2021: Shares issued $1.2MFY2021: Capital spending −$247KFY2021: Dividends −$871K$1.2MFY2021FY2022: Operating cash flow −$22.9MFY2022: Net borrowing $2.7MFY2022: Shares issued $90KFY2022: Capital spending −$367KFY2022: Acquisitions −$1.0MFY2022: Dividends −$3.1M$2.8MFY2022FY2023: Operating cash flow $8.8MFY2023: Net borrowing $21.8MFY2023: Shares issued $10.1MFY2023: Capital spending −$204KFY2023: Dividends −$3.1M$40.7MFY2023FY2024: Operating cash flow $17.5MFY2024: Net borrowing −$328KFY2024: Shares issued $120KFY2024: Capital spending −$1.5MFY2024: Dividends −$3.1M$17.6MFY2024FY2025: Operating cash flow $8.3MFY2025: Net borrowing −$18.7MFY2025: Shares issued $8.7MFY2025: Capital spending −$1.9MFY2025: Buybacks −$270KFY2025: Dividends −$3.1M$17.0MFY2025
Over these 5 years operating cash flow totalled −$21.4M; the largest uses were operating cash flow ($56.0M) and net borrowing ($19.0M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$25.1M
Debt$15.9M
Net cash$9.2M
Cash runway2.3 years

LifeMD is burning cash: its operations consume cash, a free cash flow of −$11.1M a year at the current rate against $25.1M of cash and investments: a runway of about 2.3 years before any new financing.

Where the cash came from and went

LifeMD: sources (+) and uses (−) of cash, Q2 2026LifeMD: sources (+) and uses (−) of cash, Q2 2026Cash drawn (+) / kept (−)$9.3MOperating cash flow−$6.9MCapital spending−$1.7MDividends−$777KOther investing$66K
LifeMD: sources (+) and uses (−) of cash, TTM to Q2 2026LifeMD: sources (+) and uses (−) of cash, TTM to Q2 2026Cash drawn (+) / kept (−)$11.1MOther investing$10.9MOperating cash flow−$9.9MOther financing−$7.9MDividends−$3.1MCapital spending−$1.1M

From profit to cash

LifeMD: net income to operating cash flow, Q2 2026LifeMD: net income to operating cash flow, Q2 2026Net income−$7.1MDepreciation & amortization$325KStock-based pay$790KReceivables−$1.4MInventory$221KPayables−$3.5MAccrued liabilities$1.7MDeferred revenue$44.8MContract assets$88KPrepaid and other assets$1.4MOperating cash flow−$6.9M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q2 20262053343-270
Q1 20261745272-210
Q4 202512167366-178
Q3 20251342272-218
Q2 20251641266-208
Q1 20251832147-97
Q4 202413837181-6
Q3 20241043284-230

Every quarter

QuarterOperating cash flowCapital spendingBuybacksDividendsNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$6.9M−$1.7M—−$777K——$9.3M−$8.6M
Q1 2026$445K−$2.0M—−$777K—$81K$2.3M−$1.6M
Q4 2025−$3.3M−$155K—−$777K——−$13.0M−$3.4M
Q3 2025−$147K−$821K−$270K−$777K−$16.7M$8.7M$12.4M−$968K
Q2 2025$8.6M−$2.8M—−$777K——−$1.8M$5.8M
Q1 2025$3.1M−$2.0M—−$777K——$612K$1.1M
Q4 2024$1.1M−$198K—−$777K—$12K$2.6M$875K
Q3 2024$6.7M−$448K—−$777K−$13K—−$1.9M$6.3M

LifeMD: income statement and cash flow

LifeMD, Q2 2026: revenue $47.3M (-4% year over year), operating margin -15.1%. The chart follows the revenue to costs, profit and cash.

LifeMD: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.